PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
21 enrolled
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1 Terminated
50 enrolled
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Phase 1 Terminated
88 enrolled 18 charts
MK-2140-002
Phase 2 Terminated
102 enrolled 36 charts
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Phase 1 Terminated
58 enrolled
DisTinGuish
Phase 2 Terminated
247 enrolled 38 charts
Futibatinib in Patients With Specific FGFR Aberrations
Phase 2 Terminated
115 enrolled 19 charts
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Phase 1 Terminated
44 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Phase 1 Terminated
19 enrolled
STARBURST
Phase 2 Terminated
11 enrolled
nextHERIZON
Phase 2 Terminated
7 enrolled 8 charts
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Phase 1/2 Terminated
87 enrolled 29 charts
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
A Study of SGN-ALPV in Advanced Solid Tumors
Phase 1 Terminated
43 enrolled
A Study of SGN-STNV in Advanced Solid Tumors
Phase 1 Terminated
111 enrolled
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Phase 1 Terminated
79 enrolled 42 charts
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Phase 1/2 Terminated
1 enrolled
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Phase 2 Terminated
29 enrolled
CAR
Phase 1 Terminated
9 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Phase 1/2 Terminated
13 enrolled 24 charts
DIGEST
Phase 3 Terminated
361 enrolled 18 charts
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Phase 2 Terminated
62 enrolled 28 charts
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
Phase 2 Terminated
6 enrolled
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
46 enrolled 21 charts
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
FIDES-03
Phase 1/2 Terminated
47 enrolled 22 charts
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
Systems Biology of Gastrointestinal and Related Diseases
Terminated
17 enrolled
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Phase 1 Terminated
14 enrolled 20 charts
LODESTAR
Phase 2 Terminated
83 enrolled 16 charts
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Phase 1 Terminated
11 enrolled 10 charts
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 29 charts
MK-3475-063
Phase 3 Terminated
94 enrolled 17 charts
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Phase 1/2 Terminated
2 enrolled 9 charts
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Phase 1 Terminated
60 enrolled
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Phase 1/2 Terminated
140 enrolled
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Phase 1/2 Terminated
12 enrolled
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Phase 1 Terminated
39 enrolled
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
Phase 2 Terminated
21 enrolled
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Phase 1 Terminated
16 enrolled